Related Experiment Video
Updated: Aug 15, 2026

Vaccinia Reporter Viruses for Quantifying Viral Function at All Stages of Gene Expression
Published on: May 15, 2014
Novel and specific inhibitors of a poxvirus type I topoisomerase
Alexis Bond1, Zachary Reichert, James T Stivers
1Department of Pharmacology and Molecular Sciences, The Johns Hopkins University, School of Medicine, Baltimore, MD 21205-2185, USA.
Abstract:
Vaccinia DNA topoisomerase (vTopo) is a prototypic pox virus family topoisomerase that shares extensive structural and mechanistic properties with the human type IB enzyme (hTopo) and is important for viral replication. Despite their far-reaching similarities, vTopo and hTopo have surprisingly distinct pharmacological properties. To further exploit these differences, we have developed recently the first high-throughput screen for vTopo, which has allowed rapid screening of a 1990-member small-molecule library for inhibitors. Using this approach, 21 compounds were identified with IC(90) values less than 10 muM, and 19 of these were also found to inhibit DNA supercoil relaxation by vTopo. Four of the most potent compounds were completely characterized and are structurally novel topo I inhibitors with efficacies at nanomolar concentrations. These inhibitors were highly specific for vTopo, showing no inhibition of the human enzyme even at 500- to 2000-fold greater concentrations. We describe a battery of efficient experiments to characterize the unique mechanisms of these vTopo inhibitors and discuss the surprising promiscuity of this enzyme to inhibition by structurally diverse small molecules.
Insights
Researchers identified novel small-molecule inhibitors targeting vaccinia DNA topoisomerase (vTopo), crucial for viral replication. These compounds are highly specific for vTopo, showing no inhibition against the human enzyme, offering potential therapeutic avenues.
Area of Science:
- Biochemistry
- Molecular Biology
- Virology
Background:
- Vaccinia DNA topoisomerase (vTopo) is essential for poxvirus replication and shares similarities with human topoisomerase I (hTopo).
- Despite structural similarities, vTopo and hTopo exhibit distinct pharmacological profiles, presenting an opportunity for targeted drug development.
Purpose of the Study:
- To develop and implement a high-throughput screening (HTS) assay for identifying vTopo inhibitors.
- To characterize novel small-molecule inhibitors that selectively target vTopo over hTopo.
Main Methods:
- A high-throughput screen of a 1990-member small-molecule library was conducted against vTopo.
- Inhibitory activity was assessed by measuring DNA supercoil relaxation.
- Potent inhibitors were further characterized using various biochemical assays to determine their mechanism of action and specificity.
Main Results:
- The HTS identified 21 compounds with IC(90) values below 10 muM, with 19 inhibiting vTopo DNA supercoil relaxation.
- Four novel, potent vTopo inhibitors were characterized, demonstrating nanomolar efficacy.
- These inhibitors exhibited high specificity for vTopo, with no observed inhibition of hTopo even at significantly higher concentrations (500- to 2000-fold).
Conclusions:
- Novel, highly specific vTopo inhibitors have been discovered using a new HTS assay.
- These compounds represent promising leads for antiviral therapies targeting poxviruses.
- The study highlights the distinct pharmacological properties of vTopo and its susceptibility to diverse small-molecule inhibitors.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
DNA Topoisomerases
Types and Mechanism of action
Topoisomerases are divided into two main types. Type I...
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Inhibitors of Virion Maturation and Assembly
Inhibitors Of Virion Release

